Dean Eliott MD
Retinal Disease
Professor, Harvard Medical School, Director Emeritus of Retina Service, Director of Surgical Retina Fellowship
Join to View Full Profile
Harvard Medical School243 Charles StBoston, MA 02114
Phone+1 617-573-3701
Dr. Eliott is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Dean Eliott is a retina specialist in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital, Brigham and Women's Hospital, and Massachusetts Eye and Ear. He received his medical degree from Vanderbilt University School of Medicine and has been in practice 30 years. He is experienced in diabetic retinopathy, macular degeneration, retina surgery, and vitreoretinal disease. He has more than 300 publications.
Education & Training
Duke University HospitalChief Residency, Ophthalmology, 1993 - 1994- Duke University HospitalFellowship, Surgical Retina and Vitreous, 1992 - 1993
Johns Hopkins UniversityResidency, Ophthalmology, 1989 - 1992
New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 1988 - 1989
Vanderbilt University School of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 2006 - Present
MA State Medical License 2011 - 2025
MI State Medical License 1994 - 2007
NC State Medical License 1992 - 1998
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Avastin for PDR (Proliferative Diabetic Retinopathy) Start of enrollment: 2009 Jun 01
- Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration Start of enrollment: 2011 Jun 09
- Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD Start of enrollment: 2013 Feb 25
Publications & Presentations
PubMed
- Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD.Marta Stevanovic, Nicole Koulisis, Tom Chen, Stavros N Moysidis, Bruce Burkemper
Journal of Vitreoretinal Diseases. 2025-04-21 - Retinal Vasculopathy and Choroiditis after Pegcetacoplan Injection: Clinicopathologic Support for a Drug Hypersensitivity Reaction.Ankur Nahar, Dean Eliott, Robert L Avery, Jose Pulido, Ralph C Eagle Jr
Ophthalmology. Retina. 2025-04-01 - 1 citationsIntravitreal Antibiotics versus Early Vitrectomy Plus Intravitreal Antibiotics for Postinjection Endophthalmitis: An IRIS® (Intelligent Research in Sight Registry) Ana...Connor J Ross, Sophia Ghauri, Joshua B Gilbert, Daniel Hu, Varun Ullanat
Ophthalmology. Retina. 2025-03-01
Press Mentions
He Kept Seeing Sparkly Dots on the Edge of His Vision. What Was It?June 16th, 2021
Scleral Buckle Infection with Pseudallescheria BoydiiSeptember 23rd, 2020
Predictive Value of the OCT Double-Layer Sign for Identifying Subclinical Neovascularization in Age-Related Macular DegenerationOctober 30th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
